Apple defeats AliveCor bid to block U.S. Apple Watch imports

On Friday, Apple successfully persuaded a U.S. appeals court to sustain its victory over medical device company AliveCor in a patent dispute that might have resulted in an import ban on Apple Watches. The U.S. Court of Appeals for the Federal Circuit upheld the decision, declaring AliveCor’s heart-rate monitoring patents invalid—patents that AliveCor claimed Apple had infringed. This ruling overturned a prior decision by a U.S. trade tribunal, which had found Apple in violation of AliveCor’s patent rights.
Blake Brittain for Reuters:
‎

Mountain View, California-based AliveCor sought a ban on Apple Watch imports at the U.S. International Trade Commission in 2021. It accused the tech giant of infringing three patents related to AliveCor’s KardiaBand, an Apple Watch accessory that monitors a user’s heart rate, detects irregularities and performs an electrocardiogram to identify heart problems like atrial fibrillation.
The U.S. Patent Office’s Patent Trial and Appeal Board invalidated the patents at Apple’s request in 2022. The ITC determined weeks later that AliveCor would be entitled to an import ban on infringing Apple Watches if the patents were valid, but paused the ban while the Federal Circuit considered appeals.
The Federal Circuit agreed with Apple on Friday that AliveCor’s patents were invalid and dismissed the ITC case.

‎
MacDailyNews Take: Good luck with those appeals, DeadCor.